(2S)-2-amino-3-(4-(6-(2,2,2-trifluoro-1-(4-fluoro-2-(thiophen-2-yl)phenyl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid | 1033806-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (2S)-2-amino-3-(4-(6-(2,2,2-trifluoro-1-(4-fluoro-2-(thiophen-2-yl)phenyl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid
• 英文别名: (2S)-2-amino-3-(4-(6-(2,2,2-trifluoro-1-(4-fluoro-2-(thiophen-2-yl)phenyl)ethoxy)pyrimidin-4-yl)phenyl)propionic acid；(2S)-2-amino-3-[4-[6-[2,2,2-trifluoro-1-(4-fluoro-2-thiophen-2-ylphenyl)ethoxy]pyrimidin-4-yl]phenyl]propanoic acid
• CAS: 1033806-30-2
• 化学式: C₂₅H₁₉F₄N₃O₃S
• 分子量: 517.504
• InChiKey: KHXIHAYRYWOTSG-HSTJUUNISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• METHODS OF PREVENTING AND TREATING LOW BONE MASS DISEASES
  申请人：Karsenty Gerard

  公开号：US20110281899A1

  公开（公告）日：2011-11-17

  The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.

  本发明提供了降低或增加患者血清5-羟色胺水平以增加或减少骨量的方法和治疗剂。在优选实施例中，患者已知患有或有患低骨量疾病（如骨质疏松症）的风险，治疗剂为TPH1抑制剂或5-羟色胺受体拮抗剂。
• [EN] METHODS OF PREVENTING AND TREATING LOW BONE MASS DISEASES<br/>[FR] PROCÉDÉS DE PRÉVENTION ET DE TRAITEMENT DE MALADIES DE FAIBLE MASSE OSSEUSE
  申请人：UNIV COLUMBIA

  公开号：WO2010056992A1

  公开（公告）日：2010-05-20

  The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1inhibitors or serotonin receptor antagonists.

  本发明提供了降低或增加患者血清5-羟色胺水平的方法和治疗剂，以分别增加或降低骨量。在优选实施例中，患者已知患有或有患低骨量疾病（如骨质疏松症）的风险，治疗剂为TPH1抑制剂或5-羟色胺受体拮抗剂。
• ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE
  申请人：TerSera Therapeutics LLC

  公开号：EP3808740A1

  公开（公告）日：2021-04-21

  Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders.

  本研究公开了式 I 的化合物，以及包含这些化合物的组合物和使用这些化合物治疗、预防和/或控制疾病和失调的方法。
• 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2589600B1

  公开（公告）日：2017-02-15
• 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP3176159B1

  公开（公告）日：2020-10-21